Polycystic Kidney Disease - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 93 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2017, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 1, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Polycystic Kidney Disease - Overview 8
Polycystic Kidney Disease - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Polycystic Kidney Disease - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Polycystic Kidney Disease - Companies Involved in Therapeutics Development 25
Angion Biomedica Corp 25
Aptevo Therapeutics Inc 25
Celgene Corp 26
Conatus Pharmaceuticals Inc 26
DiscoveryBiomed Inc 27
Endocyte Inc 27
IC-MedTech Inc 28
Ipsen SA 28
Kadmon Corp LLC 29
Madrigal Pharmaceuticals Inc. 29
ManRos Therapeutics 30
Metabolic Solutions Development Company LLC 30
Mironid Ltd 30
NovaTarg Therapeutics Inc 31
Otsuka Holdings Co Ltd 31
Q BioMed Inc 32
Regulus Therapeutics Inc 32
XORTX Pharma Corp 32
Polycystic Kidney Disease - Drug Profiles 33
(sodium ascorbate + menadione sodium bisulfite) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ANG-3070 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CIM-2 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CR-8 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DBM-43H11 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Drug for Cystic Kidney Disease - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
EC-0371 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
IDN-8050 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
JP-153 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
lanreotide acetate - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
lixivaptan - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
menadione sodium bisulfite - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
MSDC-0160 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
oxypurinol - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
pyrimethamine - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
RGLS-4326 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
ricolinostat - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Small Molecules to Inhibit PDE4 for Polycystic Kidney Disease and Oncology - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
STA-2842 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
tesevatinib tosylate - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
TNFR x TWEAKR - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
tolvaptan - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Polycystic Kidney Disease - Dormant Projects 81
Polycystic Kidney Disease - Discontinued Products 82
Polycystic Kidney Disease - Product Development Milestones 83
Featured News & Press Releases 83
Oct 04, 2017: Palladio Biosciences Receives Orphan Drug Designation from the U.S. FDA for Lixivaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease 83
Jun 12, 2017: Palladio Biosciences Announces Appointment of Frank C. Condella, Jr. to Board of Directors 83
Jun 12, 2017: Regulus Announces Pipeline Update and Advancement on RGLS-4326 84
May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S 84
May 22, 2017: Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S. 84
Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan 85
Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD 85
Dec 06, 2016: Regulus Announces Update on RGLS4326 85
Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016 86
Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease 86
Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015 87
May 28, 2015: Otsuka's JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease 88
Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented "dual action" small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases 89
Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease 90
Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease 90
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93

List of Tables

Number of Products under Development for Polycystic Kidney Disease, H2 2017 9
Number of Products under Development by Companies, H2 2017 11
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Universities/Institutes, H2 2017 13
Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
Products under Development by Universities/Institutes, H2 2017 16
Number of Products by Stage and Target, H2 2017 18
Number of Products by Stage and Mechanism of Action, H2 2017 20
Number of Products by Stage and Route of Administration, H2 2017 22
Number of Products by Stage and Molecule Type, H2 2017 24
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H2 2017 25
Polycystic Kidney Disease - Pipeline by Aptevo Therapeutics Inc, H2 2017 25
Polycystic Kidney Disease - Pipeline by Celgene Corp, H2 2017 26
Polycystic Kidney Disease - Pipeline by Conatus Pharmaceuticals Inc, H2 2017 26
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H2 2017 27
Polycystic Kidney Disease - Pipeline by Endocyte Inc, H2 2017 27
Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, H2 2017 28
Polycystic Kidney Disease - Pipeline by Ipsen SA, H2 2017 28
Polycystic Kidney Disease - Pipeline by Kadmon Corp LLC, H2 2017 29
Polycystic Kidney Disease - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 29
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, H2 2017 30
Polycystic Kidney Disease - Pipeline by Metabolic Solutions Development Company LLC, H2 2017 30
Polycystic Kidney Disease - Pipeline by Mironid Ltd, H2 2017 30
Polycystic Kidney Disease - Pipeline by NovaTarg Therapeutics Inc, H2 2017 31
Polycystic Kidney Disease - Pipeline by Otsuka Holdings Co Ltd, H2 2017 31
Polycystic Kidney Disease - Pipeline by Q BioMed Inc, H2 2017 32
Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, H2 2017 32
Polycystic Kidney Disease - Pipeline by XORTX Pharma Corp, H2 2017 32
Polycystic Kidney Disease - Dormant Projects, H2 2017 81
Polycystic Kidney Disease - Discontinued Products, H2 2017 82